SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Aptevo Reports Fewer Mipletamig Infusion Reactions After Dose-Regimen Refinement

Aptevo Therapeutics reported substantially fewer infusion-related reactions after refining mipletamig’s priming-dose regimen, advancing tolerability objectives for frontline AML development.

APVO
SquawkNews Desk

Related stories

Maire to Acquire Natural Gas Liquefaction Process Technologies From Chart Industries M impact | EQUITY | Nov 15, 2026, 07:53 PM UTC US Air Travel Disruptions Continue for Third Day, 5,200 Flights Affected More than 5,200 flights had been affected by Sunday as airlines worked to restore schedules. Transportation Secretary Sean Duffy predicted a return to normal by Monday. M impact | EQUITY | Nov 15, 2026, 04:45 PM UTC Duffy Says US Air Travel Disruption Will End by Tomorrow Transportation Secretary Sean Duffy told NBC the disruption would be over by the end of today or tomorrow. L impact | EQUITY | Nov 15, 2026, 02:24 PM UTC US Air Travel Disruption Expected to End by Tomorrow, Duffy Says Transportation Secretary Sean Duffy told NBC the US air travel disruption will be over by the end of today or tomorrow. L impact | EQUITY | Nov 15, 2026, 02:05 PM UTC Transportation Secretary Duffy Says US Air Travel Disruption Will End Soon Duffy told NBC the disruption would be over by “end of today, end of tomorrow.” L impact | EQUITY | Nov 15, 2026, 02:05 PM UTC ESS Tech Files for Chapter 7 Bankruptcy and Ceases Operations ESS Tech filed for Chapter 7 bankruptcy and terminated all employees and officers without cause. The iron flow battery company said it took the action after considering available s M impact | EQUITY | Nov 15, 2026, 02:04 PM UTC